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RESUMO
Introdução: A esclerose múltipla caracteriza-se pela presença de lesões inflamatórias a nível do encéfalo e medula espinhal. A 
ressonância magnética é atualmente um exame indispensável no diagnóstico, na avaliação da atividade da doença e na resposta 
ao tratamento. Embora na nossa prática as vantagens da ressonância magnética estejam bem estabelecidas, continuam a existir 
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ABSTRACT
Introduction: Magnetic resonance imaging is established as a recognizable tool in the diagnosis and monitoring of multiple sclerosis 
patients. In the present, among multiple sclerosis centers, there are different magnetic resonance imaging sequences and protocols 
used to study multiple sclerosis that may hamper the optimal use of magnetic resonance imaging in multiple sclerosis. In this context, 
the Group of Studies of Multiple Sclerosis and the Portuguese Society of Neuroradiology, after a joint discussion, appointed a committee 
of experts to create recommendations adapted to the national reality on the use of magnetic resonance imaging in multiple sclerosis. 
The purpose of this document is to publish the first Portuguese consensus recommendations on the use of magnetic resonance 
imaging in multiple sclerosis in clinical practice.
Material and Methods: The Group of Studies of Multiple Sclerosis and the Portuguese Society of Neuroradiology, after discussion of 
the topic in national meetings and after a working group meeting held in Figueira da Foz on May 2017, have appointed a committee of 
experts that have developed by consensus several standard protocols on the use of magnetic resonance imaging in the diagnosis and 
follow-up of multiple sclerosis. The document obtained was based on the best scientific evidence and expert opinion. Subsequently, 
the majority of Portuguese multiple sclerosis consultants and departments of neuroradiology scrutinized and reviewed the consensus 
paper; comments and suggestions were considered. Technical magnetic resonance imaging protocols regarding diagnostic, monitoring 
and the recommended information to be included in the magnetic resonance imaging report will be published in a separate paper.
Results: We provide some practical guidelines to promote standardized strategies to be applied in the clinical practice setting of 
Portuguese healthcare professionals regarding the use of magnetic resonance imaging in multiple sclerosis.
Conclusion: We hope that these first Portuguese magnetic resonance imaging guidelines, based in the best available clinical evidence 
and practices, will serve to optimize multiple sclerosis management and improve multiple sclerosis patient care across Portugal.
Keywords: Demyelinating Diseases; Magnetic Resonance Imaging; Multiple Sclerosis; Practice Guidelines as Topic
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dificuldades técnicas (uso de sequências e protocolos não padronizados) e clínicas (frequência de exames não adequada) que podem 
dificultar o diagnóstico e o seguimento dos doentes. Neste contexto, o Grupo de Estudos de Esclerose Múltipla e a Sociedade 
Portuguesa de Neurorradiologia, após discussão conjunta, designaram um comité de peritos para a criação de recomendações 
adaptadas à realidade nacional sobre a utilização da ressonância magnética na esclerose múltipla. O objetivo deste documento é 
publicar as primeiras recomendações de consenso portuguesas sobre a utilização da ressonância magnética na esclerose múltipla 
na prática clínica.
Material e Métodos: O Grupo de Estudos de Esclerose Múltipla e a Sociedade Portuguesa de Neurorradiologia, após discussão 
do tema em reuniões de âmbito nacional e de uma reunião do grupo de trabalho que teve lugar na Figueira da Foz em maio de 
2017, designaram um comité de peritos que elaboraram por método de consenso vários protocolos padronizados sobre o uso da 
ressonância magnética no diagnóstico e seguimento da esclerose múltipla. O documento teve como base a melhor evidência científica 
e a opinião dos peritos. Posteriormente, o documento foi enviado para escrutínio à maioria dos responsáveis de consulta de esclerose 
múltipla e dos departamentos de neurorradiologia; os comentários e sugestões foram considerados. Os protocolos técnicos referentes 
à aquisição de imagem e a informação que deverá constar no relatório destes exames serão publicados numa publicação separada.
Resultados: Neste artigo são propostas várias orientações práticas para promover estratégias padronizadas para serem aplicadas 
na prática clínica dos profissionais de saúde portugueses no que se refere ao uso da ressonância magnética na esclerose múltipla.
Conclusão: Os autores esperam que estas primeiras orientações portuguesas, sobre a utilização da ressonância magnética na 
esclerose múltipla na prática clínica, baseadas nas melhores evidências e práticas clínicas disponíveis, sirvam para otimizar a gestão 
da esclerose múltipla e melhorar o tratamento destes doentes em Portugal.
Palavras-chave: Doenças Desmielinizantes; Esclerose Múltipla; Protocolos; Ressonância Magnética
INTRODUCTION
 Multiple sclerosis (MS) is a chronic autoimmune 
demyelinating inflammatory and degenerative disease of 
the central nervous system (CNS) that affects people usually 
between 17 and 65 years old and is twice as common in 
women than men.1 MS may cause permanent disability 
and affects patients’ quality of life negatively.1 Portugal is 
a medium risk country for MS with an estimated incidence 
in 1998 - 2007 of 4.48 per 100 000 habitants in northern 
Lisbon, Portugal.2
 Due to its high sensibility and specificity in detecting 
demyelinating lesions and differential diagnosis capability, 
since 2001, brain and spinal cord magnetic resonance 
imaging (MRI) is included in MS diagnostic criteria.3-5 MRI 
diagnostic value was recently stressed in the revision 
of the MAGNIMS MS diagnostic criteria.6 However, 
MRI importance in MS is not confined to its diagnosis, 
since it has a well-known role in the understanding of its 
pathophysiology, in phenotype descriptions, in prognosis, in 
monitoring of individual therapeutic responses, in monitoring 
potential MS treatments adverse effects and, finally, as a 
surrogate marker in clinical trials.7-10
 At present, in Portugal as in other countries, there 
are different MRI sequences and protocols used to study 
MS; moreover, the frequency and the clinical situations in 
which this test is performed in MS also vary among MS 
centers.9,11,12 This may hamper and negatively influence the 
optimal use of MRI in MS.9,11-13 To overcome this problem 
standardized protocols and guidelines on the optimal use 
of MRI were published.8,9,12-19 In Portugal, after several 
meetings and clinical discussions, neurologists and 
neuroradiologists dedicated to MS patients’ treatment have 
decided that there was a need to create a standardized 
protocol and guidelines, adapted to our national reality, on 
the use of MRI in MS, as recognized by other experts in the 
field.8,20
 The goal of this document is to publish a Portuguese 
consensus recommendations agreement regarding the use 
of MRI in MS, on the clinical practice setting, based on the 
professional experience and the best scientific evidence. 
It is our hope that these recommendations and guidance 
may be implemented in everyday clinical practice, in our 
nationwide MS centers and Neuroradiology departments.
MATERIAL AND METHODS
 In 2017 the Grupo de Estudos de Esclerose Múltipla 
(GEEM, the main Portuguese healthcare professionals 
group dedicated to MS study and treatment, supported by 
the Portuguese Neurological Society) and the Portuguese 
Society of Neuroradiology (SPNR) nominated, from among 
their respective members, a group of experts, originating 
from academic and community-based MS centers, to 
convey and write the first draft of a consensus, based on the 
best available scientific evidence and clinical expertise. After 
several rounds of internal discussions, the expert-group 
consensus recommendations agreement and standardized 
protocols on the use of MRI in the diagnosis and monitoring 
of MS, were circulated by among the members of the two 
scientific societies, for suggestions and feedback which 
were then synthesized and incorporated in the final version 
of the manuscript. Technical MRI protocols regarding 
diagnostic, monitoring and the recommended information to 
be included in the MRI report will be published in a separate 
paper.
RESULTS
1. MRI and MS diagnosis 
 The diagnosis of MS is based on clinical evaluation and 
in the demonstration of demyelinating lesions dissemination 
in space (DIS) and time (DIT) and exclusion of alternative 
disorders that can mimic this condition.4
 MRI has high sensibility to detect MS lesions, is widely 
available, reproducible, and provides objective measures 
of disease activity and burden, so and without surprise 
it became, since 2001, with the publication of the now 
extensively accepted MS McDonald criteria, a mainstay of 
MS diagnosis.3,16 These criteria incorporated, for the first 
time, brain and spinal lesions in the MS diagnostic algorithm 
and introduced the definition of MRI DIS and DIT.3,8 In 2005 
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and 2010 the McDonald criteria suffered revisions that 
simplified the demonstration of lesion DIT, better defined 
the role of spinal cord lesions in demonstrating DIS and 
simplified primary-progressive MS diagnosis (Table 1).4,5,8,21
 It is now well accepted that the McDonald criteria allowed 
clinicians to accurately make a MS diagnosis sooner, which 
permitted an earlier start of a disease-modifying treatment 
(DMT) and had a favorable impact in MS prognosis.8,16
 Nevertheless, the last revised McDonald criteria have 
been criticized for their complexity, their somewhat low 
diagnostic specificity, that may lead to overdiagnosis, 
the absence of other paraclinical tests in the diagnostic 
algorithm, such as cerebrospinal fluid (CSF) study, which 
may be useful in the differential diagnosis of patients that 
don’t fulfill MRI criteria or have unusual or uncertain MS 
presentations, and finally for limitations in the diagnosis of 
primary progressive MS (PPMS).12
 To rule out these issues the European collaborative 
research group that studies MRI in MS (MAGNIMS) 
proposed a new MRI MS diagnosis criteria consensus 
guideline (Table 2) in 2016 and latter on the McDonald 
criteria (Table 3) were updated in 2017.6,22 Nevertheless 
and in spite of the overall expectations, the 2017 McDonald 
criteria did not take into account all the proposed DIS 
MAGNINS MRI MS criteria (particularly they didn´t accept 
three or more periventricular lesions and one or more optic 
nerve lesion as DIS criteria), they advanced a MS diagnosis 
in a typical clinical isolated syndrome (CIS) if DIS and 
cerebrospinal fluid (CSF)-specific oligoclonal bands (OCBs) 
are present and maintained the PPMS criteria (Table 3).6,22
 In the 2017 McDonald criteria, on a CIS case, if there is 
a typical clinical presentation of MS and no other disease 
that would better explain the patient clinical features is 
suspected, a diagnosis of possible MS may be done.22 
Table 1 - MS diagnosis criteria (adapted from ref. 4)
McDonald criteria, 2010 revisions
DIS can be demonstrated by 1 T2 lesions in at least 2 of 4 areas of the CNS:
  Periventricular
  Juxtacortical
  Infratentorial
  Spinal cord
DIT can be demonstrated by:
  1. A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, with reference to a baseline scan, irrespective of the timing of 
      the baseline MRI and/or,
  2. Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions at any time.
PPMS may be diagnosed in subjects with:
    One year of disease progression (retrospectively or prospectively determined).
    Plus 2 of the 3 following criteria:
  - Evidence for DIS in the brain based on one or more T2 lesions in at least 1 area characteristic for MS (periventricular, 
       juxtacortical, or infratentorial).
    - Evidence for DIS in the spinal cord based on two or more T2 lesions in the cord.
    - Positive CSF (isoelectric focusing evidence of OCBs and/or elevated IgG index).
Table 2 - MS diagnosis criteria (adapted from ref. 6)
MAGNIMS MRI Criteria, 2016
Dissemination in space can be shown by involvement of at least two of five areas of the CNS as follows:
  Three or more periventricular lesions
  One or more infratentorial lesion
  One or more spinal cord lesion
  One or more optic nerve lesion
  One or more cortical or juxtacortical lesion
Dissemination in time can be demonstrated by:
  1. A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, with reference to a baseline scan, irrespective of the timing of 
      the baseline MRI.
  2. Simultaneous presence of gadolinium-enhancing and non-enhancing lesions at any time.
In primary progressive multiple sclerosis:
  - Identical criteria for dissemination in space should be used for primary progressive multiple sclerosis and relapse-onset multiple 
     sclerosis.
  - CSF results should be considered for clinically uncertain cases of primary progressive multiple sclerosis.
N
O
R
M
A
S O
R
IEN
TA
Ç
Ã
O
284Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                
Abreu P, et al. First Portuguese consensus recommendations for the use of magnetic resonance imaging in MS, Acta Med Port 2018 May;31(5):281-289
These criteria also recommend that at the time of diagnosis, 
a provisional disease course (relapsing-remiting, primary or 
secondary progressive MS) and if it the course is active or 
progressive (based on the previous year‘s history) should 
be specified and periodically re-evaluated based on the 
accumulated information.22
 We recommend that the 2017 revised McDonald 
criteria22 should be used for the diagnosis of MS when 
applicable.
 Until now, in spite of the importance of MRI in MS 
diagnosis, McDonald criteria and subsequent revisions 
don’t suggest how MRI sequences must be acquired, nor is 
it established in the Portuguese guidelines of MS Care.23,24 
Recently, and to obviate this issue MRI expert guidelines 
were published suggesting a specific multi-sequence brain 
and spinal cord protocol in MS diagnosis and monitoring, 
being the diagnosis protocol more extensive due to 
differential diagnosis purposes.12-14
 We recommend that a national diagnosis standardized 
MRI protocol, adapted to the Portuguese MS reality and 
based on the best and most recent scientific evidence, 
should be implemented. We also suggest that the adopted 
MRI protocols should warrant that MRI scans must be 
technically adequate, standardized and well positioned 
Table 3 - MS diagnosis criteria (adapted from ref. 21)
McDonald criteria, 2017 revisions
Dissemination in space can be shown by one or more characteristic multiple sclerosis T2-hyperintense lesions in two or more of four 
areas of the CNS*:
  Periventricular
  Cortical or juxtacortical lesion
  Infratentorial
  Spinal cord lesion
Dissemination in time can be demonstrated by:
  1. New T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI*, with reference to a baseline scan, irrespective of the timing of 
       the baseline MRI or,
   2. Simultaneous presence of gadolinium-enhancing and nonenhancing lesions at any time.
In primary progressive multiple sclerosis:
  One year of disability progression independent of clinical relapse (may be determined retrospectively or prospectively).
  Plus two of the three criteria:
    - Evidence for DIS in the brain based on one or more T2 lesions in at least one area characteristic for MS (periventricular, cortical  
      or juxtacortical, or infratentorial).
    - Two or more T2-hyperintense lesions* in the spinal cord.
    - Presence of CSF-OCBs.
* no distinction between symptomatic and asymptomatic lesion is required
Table 4 - Referring physicians’ clinical information (adapted from ref. 9, 13, 16, 18)
Recommendations summary – referring physicians’ clinical information diagnostic MRI protocol should include:
Date of symptom onset and evolution;
Description of main clinical signs (i.e. subacute onset of optic neuritis, transverse myelitis or brainstem syndrome);
Description of clinical information considered important to differential diagnosis (i.e. past history of uveitis or other autoimmune 
diseases);
Special needs such as claustrophobia, movement disorders (i.e. paroxistic spams, dystonia) or severe disabled patient;
Information about potential allergies, presence of potential incompatible MRI scan material, renal impairment/function.
Recommendations summary – referring physicians’ clinical information follow-up MRI protocol should include:
Purpose of follow-up scan (disease activity, treatment-monitoring or safety/adverse effects surveillance MRI protocol);
Description of diagnosis (RIS, CIS or MS);
Description of clinical information considered important to differential diagnosis or MRI interpretation such as unexpected clinical signs, 
clinical decline, potential adverse effects;
DMT description and duration of treatment;
In PML surveillance study, description of treatment duration, JCV serostatus and previous DMT/immunosuppression (high or low risk 
patients);
Date and, if considered relevant, clinical information of last MRI performed;
Special needs such as claustrophobia, movement disorders (i.e. paroxistic spams, dystonia) or severe disabled patient;
Information about potential allergies, presence of potential incompatible MRI scans material, renal impairment/function.
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to permit future comparative analysis, should include 
instructions to perform a structured, systematic and 
comprehensive radiological report oriented to the clinical 
needs and, finally, with recommendations for referring 
physicians to provide sufficient clinical information in order 
to permit proper interpretation of imaging findings (Table 
4).12,21
Recommendations summary 
MRI and MS diagnosis 
• The 2017 revised McDonald criteria should be used for the 
diagnosis of MS when applicable.
• A national diagnosis standardized MRI protocol, adapted to 
the Portuguese MS reality and based on the best and most 
recent scientific evidence, should be implemented. 
• The adopted MRI protocol should warrant that MRI scans 
must be technically adequate, standardized and well 
positioned. 
• The adopted MRI protocols should include instructions on 
how to perform a structured, systematic and comprehensive 
radiological report oriented towards clinical needs. 
• Referring physicians should provide sufficient clinical 
information in order to allow proper interpretation of imaging 
findings. 
a)	 MRI	 and	 MS	 diagnosis	 in	 a	 demyelinating	 first	
episode or clinical isolated syndrome
 Patients with CIS are those with a first clinical presentation 
of a disease that shows characteristics of inflammatory 
demyelination that could be MS but do not fulfill criteria of 
dissemination in time.10 As shown in epidemiological and 
clinical trials, patients with CIS are at high risk of developing 
MS.10,25
 The 2017 McDonald criteria now assist a clinician in 
making a MS diagnosis in a patient with a typical clinical CIS 
(i.e. subacute onset of optic neuritis, transverse myelitis or 
brainstem syndrome) in which the clinical and MRI criteria 
for DIS are met, CSF-OCBs are present and no better 
explanation for the clinical presentation is found.22
 In patients with initial clinical symptoms suggestive of 
demyelinating disease or CIS, a good quality whole contrast 
enhanced (gadolinium) brain MRI respecting a standardized 
multi-sequence protocol with a minimum required 
sequences to aid in the diagnosis is recommended.6,9,12-17
 When available, double inversion recovery sequences 
should also be performed in order to detect cortical or 
juxtacortical lesions, since they are now part of the 2017 
McDonald DIS criteria.6,16,22 Additional MRI sequences can 
be added depending on the individual needs, clinical cases 
or differential diagnosis.9,13 MRI brain scans should be at 
least 1.5T, since high field scanners have better sensibility 
in detecting demyelinating lesions.6
 As in other countries, the access to MS experts/centers 
and MRI equipment in Portugal may vary in the different 
regions, and as a consequence patients may wait longer for 
a diagnosis.18 We agree with the recommendation stated in 
other expert MRI MS guidelines that in the presence of a 
possible demyelinating first episode, especially in patients 
with a typical CIS a diagnostic MRI should be performed 
as soon as possible, ideally, in a week since the initial 
symptoms.18 As in other matters, the interpretation of this 
recommendation must be guided by clinical common sense 
since there are cases such as spinal cord compression 
suspicion or dubious, less typical MS symptoms, in which, 
this test must be, respectively, hastened or performed in the 
timing of other routine MRI exams.18
 The demonstration of DIT, according to the 2017 
McDonald criteria, in a CIS patient may now be achieved 
by the finding of a new T2 or gadolinium-enhanced lesion 
on a follow-up MRI brain scan at any time as compared 
to a reference scan; or the simultaneous presence of 
gadolinium-enhanced lesion and non-enhancing lesions 
at any time.22 In spite of the recent clarification of the 
McDonald 2010 DIS and DIT criteria by the 2017 revision 
(no distinction needs now to be made between symptomatic 
and asymptomatic MRI lesion to establish DIT and DIS) in 
some CIS patients it will be necessary to repeat MRI scans 
to demonstrate DIT.12,22 The best timing to perform a follow-
up scan in CIS to look for evidence of DIT is debatable; 
nevertheless there are suggestions that a second MRI 
should be performed at an interval time of 3-6 months and 
a third one after 6 - 12 months if the later MRI still doesn´t 
show DIT and then annually if the patient maintains this 
condition.5,12,13 A decrease in the frequency of MRI may 
be considered when CIS patients have been relapse free 
and radiologically stable during a follow-up of 3 to 5 years 
without DMT. MRI surveillance may be stopped if patients 
remain in this condition during a longer follow-up.13
 Spinal cord MRI imaging is more difficult technically to 
perform due to the presence of artifacts and small tissue 
volume.23 Nevertheless spinal cord MRI adds diagnostic, 
prognostic and differential diagnosis value in CIS20,25-27 
and should be included in the initial MRI workup.20,25,27 It 
is well known that spinal cord MRI is especially useful in 
the following situations: a) in CIS patients with few brain 
lesions, in which the demonstration of a clinical silent spinal 
lesion may help in the fulfillment of DIS thus reducing 
the need of a subsequent MRI appointment; b) in those 
CIS patients with atypical, equivocal or inconclusive MS 
presentations; c) and in the differential diagnosis of those 
patients with a first demyelinating episode suggesting 
spinal cord involvement.6,9,13,27 In order to reduce time 
and additional contrast administration this test should be 
performed in a “one stop shop” strategy and as with MRI 
brain scans, spinal MRI should be at least 1.5T, preferably 
3.0T.12,23 CIS patients should repeat spinal MRI in cases of 
unexpected worsening, spinal cord relapses or in suspicion 
of a secondary diagnosis.9,28 In CIS, it is not advisable to 
perform serial spinal MRI in order to show DIS and DIT and 
establish a MS diagnosis, since the spinal MRI role for this 
purpose is not fully established.12
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Recommendations summary 
MRI	and	MS	diagnosis	 in	a	demyelinating	first	episode	or	
clinical isolated syndrome.
• In CIS, the revised McDonald DIS and DIT 2017 criteria 
should be used for the diagnosis of MS when applicable.
• In CIS a 1.5T preferably 3.0T, brain MRI respecting a 
standardized multisequence protocol with minimum required 
sequences to aid in the diagnosis should be performed.
• When available, double inversion recovery sequences 
should be performed in order to detect cortical or juxtacortical 
lesions. 
• In the presence of a possible demyelinating first episode, a 
diagnostic MRI should be performed as soon as possible, 
ideally, in a week since initial symptoms.
• In CIS to look for evidence of DIT a second MRI should be 
performed at an interval time of 3 - 6 months and a third one 
after 6 - 12 months if the later MRI still doesn´t show DIT and 
then annually if the patient maintains this condition.
• A decrease in the frequency of MRI may be considered 
when CIS patients have been relapse-free and radiologically 
stable during a follow-up of 3 to 5 years without DMT, MRI 
surveillance may be stopped if patients remain in this 
condition during a longer follow-up.
• Spinal cord MRI should be included in the CIS initial MRI 
workup and should be performed in a “one stop shop” 
strategy.
• It´s not advisable to perform serial spinal MRI in CIS, in 
order to show DIS and DIT, nevertheless patients should 
repeat this exam in cases of unexpected worsening, spinal 
cord relapses or in suspicion of a secondary diagnosis.
b) MRI and MS diagnosis in relapsing-remitting and 
primary progressive multiple sclerosis
 The revised 2017 McDonald criteria underpin the 
diagnosis of relapsing-remitting MS (RRMS) solely based 
on clinical DIT and DIS criteria.22 In spite of this evidence we 
recommend that even these patients should perform a brain 
MRI to confirm MS diagnosis and for differential diagnosis 
purposes.15,22
 The primary-progressive MS (PPMS) diagnosis should 
be made based on the 2017 McDonald criteria.22 PPMS 
clinically diagnosed patients should perform a brain and 
spinal MRI to confirm MS diagnosis and to exclude diseases 
that may cause progressive disability.15,22
Recommendations summary 
MRI and MS diagnosis in relapsing-remitting and primary 
progressive multiple sclerosis.
• A brain MRI to confirm MS and differential diagnosis 
purposes should be performed in patients in which the 
diagnosis RRMS may be solely based on clinical DIT and 
DIS criteria.
• PPMS patients should perform a brain and spinal MRI to 
confirm MS diagnosis, based on 2017 McDonald criteria, 
and for differential diagnosis purposes.
c) MRI and MS diagnosis in radiologically isolated 
syndrome
 The relatively easy access to brain MRI to study other 
conditions (for instance headaches) has allowed clinicians 
to come in contact with patients that present a radiologically 
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isolated syndrome (RIS), which is defined by the presence 
of brain lesions suggestive of inflammatory demyelination 
in the absence of clinical manifestations.10,12 Some of these 
MRI findings are unspecific but others are suggestive 
of a demyelinating pathology that carries a great risk of 
conversion to CIS or MS as defined by Okuda et al.29 Since 
RIS criteria were published, several clinical and radiological 
predictors, which increase the risk of clinical progression, 
were identified, such as the presence of asymptomatic 
spinal cord lesions, a higher number of T2 lesions, younger 
age, pathological visual evoked potentials and presence of 
CSF-OCBs.29-32 The MRI criteria used to establish DIT and 
DIS in MS should be applied to assess RIS as proposed by 
the MAGNIMS group.6 In this particular group of patients it 
seems important for the clinical prognosis to perform, in the 
initial workup, spinal cord imaging.13,33 In RIS management 
there are three basic approaches: ‘wait, follow or treat’.33 The 
‘wait’ strategy proposes that no further follow-up is required 
and the patient is instructed to come back if symptoms 
occur.33 The ‘follow’ strategy is considered especially 
important in those patients who have the aforementioned 
risk factors.30,33 This strategy recommends clinical and 
radiological surveillance of patients at high risk, with the first 
radiological control suggested six months after the first MRI 
scan and a second scan after 24 months33,34; other authors 
state that the time interval applied to the brain MRI follow-up 
of CIS patients should be enforced in these patients.12 
 Until now there are no consensus on the best timing, 
in RIS patients, to perform other diagnostic tests such as 
CSF study.30,33 MS diagnosis in RIS, even in those with 
MRI DIS, DIT and with OCBs in CSF, should only be 
made in the presence of clinical symptoms.6 Since there 
is no consensus we suggest that RIS patients should be 
approached in an individually case-based manner and that 
the best timing to perform follow-up brain scans should 
be discussed with patient and the neuroradiological team. 
The ‘treat’ option in RIS is also not unanimous since the 
results of DMT treatment in RIS patients have been unclear 
and these kinds of treatments are not approved for these 
patients in most countries.30 
Recommendations summary 
MRI and MS diagnosis in radiologic isolated syndrome.
• RIS patients should be approached on an individual basis. 
Nevertheless, it is acceptable, in high at risk patients, that 
the first radiological control should be done six months after 
the first brain MRI scan and a second MRI scan should be 
performed 24 months later if the later MRI still does not 
show DIT.
• In patients with DIT we recommend that CSF study should 
be done, and if CSF-OCBs are found, we consider that the 
option to treat should be discussed with the patient.
• In patients in which the wait strategy is selected or if the 
decision to treat is based upon the presence of clinical 
symptoms we recommend that only clinical surveillance 
should be made thus obviating the need of performing brain 
MRI follow-up. 
• Spinal cord MRI should be included in the RIS initial MRI 
workup and should be performed in a ‘one stop shop’ 
strategy.
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2. MRI and disease activity monitoring; therapy 
efficacy	and	adverse	therapy	effects	
a)  MRI and disease activity monitoring
 In RRMS patient’s disease activity is detected much 
more frequently in brain MRI scans than with clinical 
assessment of relapses, being the reason why this test 
is extremely useful in monitoring the disease course and 
response to treatment.10,14,16 On the other hand spinal 
cord MRI is less sensitive than brain MRI to detect new 
demyelinating lesions, particularly contrast-enhancing 
lesions and it’s thought to have a limited role in the routine 
MS follow-up.14
 We recommend that a minimum national follow-up 
standardized MRI protocol, adapted to the Portuguese MS 
reality and based on the best and most recent scientific 
evidence, should be implemented. To better monitor 
MS disease activity, as a general rule, we recommend, 
if possible, that all follow-up brain MRI exams should be 
done in the same, at least 1.5T, MRI scanner with the same 
standardized image protocol.13-15 In follow-up MRI scans 
clinicians should give accurate and relevant information in 
the MRI request form, such as pertinent clinical history and 
current DMT (Table 4), and neuroradiologists should include 
standardized terminology and information, for instance 
demyelinating lesion numbers and specific location.9 Also, 
at follow-up scans, previous scans should be available to 
correctly compare MRI scans and patients are encouraged 
to keep copies of their own exams on portable digital 
media in order to have this available when the follow-up 
examination is performed in a different imaging center or 
receive care of other health professional outside their usual 
outpatient-clinic.9,13,18
 Due to the interindividual variability of MS activity in 
patients and albeit the importance of follow-up brain MRI in 
RRMS patients, there is not a general rule that states what is 
the best time interval to perform follow up scans.13 Still, and 
to better establish individual disease activity; it is advisable 
that a follow-up brain MRI should be obtained 3-6 months 
after a first diagnostic MRI.13 Depending of disease activity 
a second MRI follow-up should be obtained 6 - 12 months 
after the first follow-up, and thereafter annually if disease 
activity remains stable.13 However it is recognized that a 
MRI should be repeated as soon as possible in unplanned 
situations such as unexpected cases of clinical deterioration, 
unexpected disease progression or breakthrough activity 
and in re-evaluation of MS diagnosis.9,18 Similar to CIS, 
repetition of spinal cord MRI in RRMS should only be done 
when atypical spinal symptoms occur or in the suspicion of 
another spinal cord disease.14,16
Recommendations summary 
MRI and disease activity monitoring
• A minimum national MS follow-up standardized MRI 
protocol adapted to the Portuguese MS reality should be 
implemented. 
• All follow-up brain MRI exams should be done in the same, 
at least 1.5T, MRI scanner with the same standardized 
image protocol. 
• In follow-up MRI exams clinicians should give important 
and relevant information in the MRI request form and 
neuroradiologists must include standardized terminology 
and information in their reports.
• Previous examinations should be available to correctly 
compare MRI scan and patients are encouraged to keep 
copies of their own exams on portable digital media in order 
to have this available when the follow-up assessment is 
done.
• It’s advisable that a follow-up brain MRI should be obtained 
3 - 6 months after a first diagnostic MRI and depending of 
disease activity a second MRI follow-up should be obtained 
6 - 12 months after the first follow-up, and thereafter annually 
if disease activity remains stable.
• Brain MRI should be repeated, as soon as possible, 
in unplanned situations, such as unexpected cases of 
clinical deterioration, unexpected disease progression or 
breakthrough activity and in re-evaluation of MS diagnosis.
• Repetition of spinal cord MRI in RRMS should only be done 
when atypical spinal symptoms occur or in the suspicion of 
another spinal cord disease.
b)	 MRI	and	therapy	efficacy	monitoring
 In order to monitor therapy efficacy and to early identify 
therapy non-responders, that will allow a prompt switch 
to a more effective treatment, in patients initiating DMT a 
follow-up MRI scan with gadolinium enhancement should 
be planed at 6 and 12 months after therapy initiation, 
then yearly thereafter.14,16,18 The timing of the first therapy 
reference scan must take into account the time that some 
drugs may take to be fully efficacious.16 If DMT change is 
thought an MRI should be considered shortly before the 
therapy replacement.13
 There is no agreement when to decrease the frequency 
of MRI examinations nonetheless it seems acceptable that 
fewer MRI imaging scans (e.g. every two or three years) 
should be done: in later stages of the disease (progressive 
MS forms) in which MRI imaging activity is low and no 
effective treatments are yet available, in clinical and 
radiological stable MS patients without a change in DMT 
and with favorable outcome disease factors and in clinical 
and radiological stable older MS patients (> 55 - 60 years-
old) without DMT and with favorable outcome disease 
factors.9,13,18
 Cerebral and spinal volume and other non-conventional 
advanced MRI techniques have shown promising results 
in MS clinical management and as markers of disease 
progression, however, they still have to be fully validated 
and standardized in order to be performed in clinical 
practice.14
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Recommendations summary 
MRI	and	therapy	efficacy	monitoring
• In patients initiating DMT a follow-up MRI scan with 
gadolinium enhancement should be planned at 6 and 12 
months after therapy initiation, then yearly thereafter
• If a DMT change is thought, an MRI should be considered 
shortly before the therapy replacement; the decrease of the 
frequency of MRI examinations in DMT treated patients may 
seem admissible in some cases. 
• Except in clinical and neuroradiological investigational 
purposes we do not recommend performing non-
conventional advanced MRI techniques in the clinical 
practice. 
c)  MRI and adverse effects monitoring
 The importance of MRI in the surveillance of potential 
therapy adverse effects was put on notice in the case of 
natalizumab-associated progressive multifocal leuko-
encephalopathy (PML), a potential life-threatening condition 
due to reactivation of the John Cunningham virus (JCV).14 
MRI is known to aid in the early detection of natalizumab-
associated PML brains lesions. It can detect these lesions 
on asymptomatic or presymptomatic PML stages, thus 
improving the patient’s survival and functional outcome.14 
Natalizumab treated patients should follow a surveillance 
MRI protocol based on JCV seropositive status, length of 
drug exposure time and previous use of immunosuppressive 
drugs.9,13,14 Higher risk PML patients (seropositive for JCV 
with > 18 months of natalizumab exposure) should perform 
a PML brain imaging protocol every 3 - 6 months.9 If there is 
any clinical change suspicious of this condition MRI should 
be anticipated.9,14 In low risk PML patients (seronegative 
JCV patients), PML brain imaging protocol should be 
done annually.14 The surveillance PML MRI protocol, 
must include T2-Flair and diffusion-weighted sequences 
in combination with conventional T2-weighed images.14 In 
cases of JCV seropositive patients that are going to switch 
from natalizumab to another DMT a baseline MRI should 
be done one month prior to switching therapy and then 
a follow-up MRI should be repeated three months after 
natalizumab cessation.13,18 MRI is also important in the in 
follow-up of PML, since it allows the early detection of the 
PML-immune reconstitution syndrome.14 The role of MRI in 
pharmacovigilance is not reduced to PML, since this test can 
be useful in the diagnosis of other treatment complications 
for instance in the detection of other opportunistic infections 
leading to encephalitis/meningitis (such as Varicella zoster 
or Listeria) and the detection of paradoxical reactions 
such as rebound inflammatory activity or overwhelming 
inflammatory demyelination that can occur with some 
DMTs.14
Recommendations summary 
MRI and adverse therapy effects monitoring
• Natalizumab treated patients should follow a surveillance 
MRI protocol based on JCV seropositive status, length of 
drug exposure time and previous use of immunosuppressive 
drugs.
• Higher risk PML patients should perform a PML brain 
imaging protocol every 3 - 6 months, or sooner in case of 
any suspicious clinical changes.
• In low risk PML (seronegative) patients a brain imaging 
protocol should be done annually.
• In JCV seropositive patients that are going to switch from 
natalizumab to another DMT a baseline MRI should be done 
one month prior to switching therapy and then a follow-up 
MRI should be repeated three months after natalizumab 
cessation. 
CONCLUSION
 MRI is established as a recognizable tool in the diagnosis 
and monitoring of MS patients. In these first Portuguese MRI 
consensus recommendations we provide some practical 
guidelines to promote standardized strategies to be applied 
in the clinical practice setting of Portuguese healthcare 
professionals. Our recommendations are based on the 
available clinical evidence and best practices; however, 
due to the rapidly changing knowledge in the MS field 
these guidelines should be periodically updated. Finally, 
we hope that these MRI guidelines will serve to optimize 
MS management and improve MS patient care throughout 
Portugal.
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